DURBAN – Aspen Pharmacare's share price leapt 12 percent on Thursday as the market digested the JSE-listed drugmaker’s results for the year to June, released after the market closed on Wednesday.
The share price closed at R94.25.
Aspen deputy chief executive Gus Attridge said in an interview yesterday that the company had put aside the challenges of the past six months and was focused on building its anaesthetics business after it invested on capital projects in geographies like South Africa, France and Germany.
He explained that the projects were aimed at building world-class manufacturing facilities to in-source a significant portion of the production for its anaesthetics business.
“We want to secure the supply of quality anaesthetics medicines to patients across the world as we had some supply challenges in Europe.